TSX closed
Loading markets…

Advertisement

Stocks

Why COSCIENS Biopharma Inc. stock is plummeting today

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:CSCI.TO

Get CSCI alerts:

Photos provided by Pexels

COSCIENS Biopharma Inc. faced a significant drop in stock price today, closing down 8.81%.

In the latest trading session, COSCIENS Biopharma Inc. (CSCI.TO) saw its stock price plummet by 8.81%, closing at CA$11.80. This decline raises concerns among investors about the company's financial stability and future prospects.

Investor takeaway: Investors should closely monitor COSCIENS Biopharma's financial disclosures and operational updates, particularly given the recent volatility in its stock price.

Advertisement

KOHO

Earn cash back with a smarter spending account

Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.

COSCIENS Biopharma Inc.

CSCI.TO

Full stock page →

CSCI.TO

COSCIENS Biopharma Inc.

Source:WealthAwesomeWealthAwesome
$4.38 (161.03%)
120 day period
$1.10$7.02$12.94Feb 10May 7Jul 31

Market cap

$7.07M

52W high

$14.80

52W low

$1.10

1W change

-7.79%

Beta

1.90

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on CSCI's historical volatility

HistoricalForecast68%95%
C$0.01C$1688.30C$3376.59C$5064.88C$6753.17C$8441.46TodayMar 25May 29Jul 31Sep 12Oct 26Dec 8

30-Day Vol

575.0%

Annualized

90-Day Vol

353.9%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$8.49

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$7.54C$1.04C$54.79
60 trading daysC$8.00C$0.48C$132.28
90 trading daysC$8.49C$0.27C$263.75

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Stock Price Decline of 8.81%

COSCIENS Biopharma's market cap now stands at approximately CA$11.2 million, reflecting investor concerns over its recent financial performance.

Bull case

If COSCIENS Biopharma can successfully address its recent challenges and meet its operational commitments, it may regain investor confidence and see a rebound in its stock price.

Bear case

Ongoing uncertainty about financial reporting and the management cease trade order could lead to further declines in the stock price, as investor sentiment remains cautious.

Recent Performance Overview

Advertisement

Today, COSCIENS Biopharma Inc. saw its stock price close at CA$11.80, an 8.81% decrease from the previous trading session. This drop has raised eyebrows among investors, particularly given the company's recent announcements regarding potential delays in financial reporting.

Investor Concerns

The decline in stock price can be attributed to a combination of factors, including a management cease trade order and concerns over the timely filing of annual financial statements. Investors are advised to keep a close eye on upcoming disclosures, as these could significantly impact stock performance.

Looking Ahead

As COSCIENS Biopharma navigates these turbulent waters, the focus will be on its ability to stabilize operations and restore investor confidence. Any updates regarding its financial health or strategic initiatives will be crucial for its recovery.

Advertisement

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: July 9, 2026
Last Updated: July 9, 2026

Sponsored links

Advertisement